Table 2. Selected Baseline Risk Factors for Incident Dyspnea

| Risk Factors for Incident Dyspnea | Missing Overall Dyspnea (%) Dyspnea (%) p Value |
|----------------------------------|-----------------------------------------------|
| n                                | 22,813 (21.57%)                              | 1036 (56.0%)                           | <0.001              |
| Age, median (Q1, Q3), years      | 0 (40.0, 66.0)                               | 0 (40.0, 66.0)                        | 0 (40.0, 66.0)      | (47.5, 87.0) | <0.001 |
| US region, n (%)                 | 728 (38.6)                                   | 710 (36.0)                            | 148 (41.6)          | <0.001                |
| West                             | 384 (38.0)                                   | 372 (37.0)                            | 9 (41.4)            | <0.001                |
| African American                 | 5222                                          | 301 (33.6)                            | 0.11                |
| Asian                            | 726 (4.3)                                    | 698 (4.2)                             | 28 (3.2)            | 0.075                 |
| Caucasian                        | 10 (80.1)                                    | 9 (80.0)                              | 2 (2.0)             | <0.001                |
| Hispanic                         | 2299                                          | 149 (15.5)                            | 0.075               |
| Not Hispanic                     | 15 (79.5)                                    | 14 (75.1)                             | 1 (0.5)             |
| Female                           | 11,330 (49.7)                                | 10,687 (49.5)                         | 543 (25.4)          | 0.005                 |
| Male                             | 11,330 (50.3)                                | 10,690 (50.5)                         | 493 (24.6)          | <0.001                |
| Overweight (%)                   | 0 (64.2)                                     | 561 (64.8)                            | 54 (24.2)           | <0.001                |
| Yes                              | 8103 (35.8)                                  | 7628 (35.4)                           | 475 (24.5)          | 0.001                 |
| High risk co-infections, median  | 0.00 (2.0)                                   | 0.00 (2.0)                            | 0.00 (2.0)          | 0.001                 |

Conclusion. In a real-world cohort, 4.6% and 0.5% of patients developed dyspnea and ILD, respectively, after COVID-19 hospitalization. Multivariate analyses suggested that LOS, age, obesity, and comorbidity burden may be risk factors for post-COVID-19 respiratory complications. Limitations included sensitivity of diagnosis codes, availability of labs, and care-seeking bias.

Disclosures. Kelly Zalocusky, PhD, F. Hoffmann-La Roche Ltd (Shareholder) Genentech, Inc. (Employee) Devika Chawla, PhD MSPH, F. Hoffmann-La Roche Ltd. (Shareholder) Genentech, Inc. (Employee) Margaret Neighbors, PhD F. Hoffmann-La Roche Ltd (Shareholder) Genentech, Inc. (Employee) Shemra Rizzo, PhD, F. Hoffmann-La Roche Ltd. (Shareholder) Genentech, Inc. (Employee) Larry Tsai, MD, F. Hoffmann-La Roche Ltd (Shareholder) Genentech, Inc. (Employee)

27. Co-infections and antimicrobial use in patients hospitalized with COVID-19

Prithiv Prasad, MD; Ioannis Zacharioudakis, MD; Jordan Poels, MD; Yania Dubrovskaya, Pharm.D., BCPS, BCIDP, AAHIVP; Dinuli Delpachitra, MD; Eduardo Burrage, MD; Signith Munoz-Gomez, MD; NYU Grossman School of Medicine, New York, NY; NYU University Grossman School of Medicine, New York, New York; NYU Grossman School of Medicine, New York, New York; NYU Langone Health, New York; NYU Long Island School of Medicine, New York, New York

Session: O-06. COVID-19 Complications, Co-infections and Clinical Outcomes I

Background. In-hospital antimicrobial use among COVID-19 patients is widespread due to perceived bacterial and fungal co-infections. We aim to describe the incidence of these co-infections and antimicrobial use in patients hospitalized with COVID-19 to elucidate data for guiding effective antimicrobial use in this population.

Methods. This retrospective study included all patients admitted with COVID-19 from January 1, 2020, to February 1, 2021 at any of the three teaching hospitals of the NYU Langone Health system. Variables of interest were extracted from the health system's de-identified clinical database. The nadir of hospital admissions between the first and second peaks of hospital admissions in the dataset was used to delineate the First Wave and Late Pandemic periods of observation. A cut-off of 48 hours after admission was used to differentiate Co-infections and Secondary infections respectively among isolates of clinically relevant bacterial or fungal pathogens in blood or sputum samples. Population statistics are presented as median with interquartile range (IQR) or total numbers with percentages.

Results. 663 of 7,213 (9.2%) inpatients were found to have a positive bacterial or fungal culture of the respiratory tract or blood during the entire course of their initial admission at our hospitals for COVID-19. Positive respiratory cultures were found in 437 (6.1%) patients, with 94 (1.3%) being collected within 48 hours of admission. Blood culture positivity occurred in 333 patients (4.6%), with 115 (1.6%) identified within 48 hours of admission. Infection-free survival decreased with duration of hospitalization, with rate of secondary infections steadily rising after the second week of hospitalization as seen in Figure 1. 70.2% of inpatients received antimicrobials for a median duration of 6 antimicrobial days (IQR 3.0 – 12.0) per patient. A higher proportion of patients received antimicrobials in the first wave than in the late pandemic period (82.6% vs. 51.8%).

Table 2.
Since COVID-19 was declared a pandemic, it has seemed that the virus is nondiscriminatory causing 3.73 million deaths worldwide. The Charleston Comorbidity Index (CCI) is a scoring system predicting the one-year mortality for patients with a range of comorbid conditions and is widely used as a predictor in clinical practice. The CCI cut-off point for each outcome (hospitalization, ICU admission and mortality) was performed, and Youden's Index was used to identify the optimal point.

Results. In the study timeframe, 9,800 patients were diagnosed with COVID-19 and of those, 48,270 were hospitalized. A one-point increase in CCI was associated with higher odds of hospitalization (OR 1.718; 95% CI 1.496-1.74). The threshold for significance to predict hospitalization was a CCI of 1.5 (AUC 0.804, Youden Index 0.48) with a specificity (73%) and sensitivity (75%). A one-point increase in CCI was associated with 1.444 higher odds of an ICU admission (95% CI 1.134-1.155). A one-point increase in CCI significantly increased the odds of discharge to hospice compared to any discharge other than hospice (OR 1.162; 95% CI 1.142-1.182)). A one-point increase in CCI score was associated with 1.188 higher odds of in-hospital mortality (95% CI 1.173-1.203) with a CCI threshold of 3.5 having the highest specificity (50.9%) and sensitivity (79.9%) to predict mortality outcome (AUC 0.704, Youden Index 0.31).

Conclusion. In conclusion CCI score is an adequate predictor of hospitalization and in hospital mortality but less so in predicting ICU admission in COVID-19 positive patients.

Disclosures. All Authors: No reported disclosures

28. Utilizing the Charleston Comorbidity Index as an Independent Predictor for Outcomes in SARS-CoV-2 Positive Patients

Irene Riestra Guaine, MD; Steven Char, MD; Ernesto Rosbalino Gonzaga, MD; Isabel Riestra, n/a; Minh Q. Ho, DO; UCF/HCA GME Consortium, Kissimmee, Florida; UCF/HCA Healthcare GME, Weehawken, New Jersey; Suffolk University, Maitland, Florida; Orlando VA Healthcare System, 14014 Deep Forest Court, Florida

Session: O-06. COVID-19 Complications, Co-infections and Clinical Outcomes 1

Background. Since COVID-19 was declared a pandemic, it has seemed that the virus is nondiscriminatory causing 3.73 million deaths worldwide. The Charleston Comorbidity Index (CCI) is a scoring system predicting the one-year mortality for patients with a range of comorbid conditions and is widely used as a predictor of prognosis and survival for a range of pathologies. This study aims to assess if there is an impact of comorbidity burden on COVID-19 patients by utilizing their CCI score.

Charleston Comorbidity Index Score

| Charleston Comorbidity Index (CCI) | Condition | Score |
|-----------------------------------|-----------|-------|
| Myocardial infarction             |           | 1     |
| Congestive Heart Failure          |           | 1     |
| Peripheral Vascular Disease       |           | 1     |
| TIA or Cerebrovascular disease    |           | 1     |
| Dementia                          |           | 1     |
| Chronic pulmonary disease         |           | 1     |
| Connective tissue disease         |           | 1     |
| Peptic ulcer disease              |           | 1     |
| Mild liver disease without portal HTN |       | 1     |
| Diabetes without end-organ damage |           | 1     |
| Hemiplegia                        |           | 2     |
| Moderate or severe renal disease  |           | 2     |
| Diabetes with end-organ damage    |           | 2     |
| Tumor without metastases (diagnosed <5years ago) |   | 2     |
| Leukemia                          |           | 2     |
| Lymphoma                          |           | 2     |
| Moderate or severe liver disease  |           | 3     |
| Metastatic solid tumor            |           | 6     |
| AIDS                              |           | 6     |

Scoring system for Charleston Comorbidity Index (CCI). Plus 1 point for every decade age 50 years and over, maximum 4 points. Higher scores indicate a more severe condition and consequently, a worse prognosis.

Methods. Multicenter, retrospective review of patients diagnosed with COVID-19 from January 2020 to September 2020 throughout the HCA Healthcare system. CCI scores for all COVID-19 positive patients were calculated and logistic regression analysis was performed to predict hospitalization and ICU admission by CCI controlling for age, sex and race. A multinomial regression model was also performed to predict discharge status by CCI controlling for age, sex and race. ROC curves to indicate the CCI cut-off point for each outcome (hospitalization, ICU admission and mortality) was performed, and Youden's Index was used to identify the optimal point.

Results. In the study timeframe, 9,800 patients were diagnosed with COVID-19 and of those, 48,270 were hospitalized. A one-point increase in CCI was associated with higher odds of hospitalization (OR 1.718; 95% CI 1.496-1.74). The threshold for significance to predict hospitalization was a CCI of 1.5 (AUC 0.804, Youden Index 0.48) with a specificity (73%) and sensitivity (75%). A one-point increase in CCI was associated with 1.444 higher odds of an ICU admission (95% CI 1.134-1.155). A one-point increase in CCI significantly increased the odds of discharge to hospice compared to any discharge other than hospice (OR 1.162; 95% CI 1.142-1.182). A one-point increase in CCI score was associated with 1.188 higher odds of in-hospital mortality (95% CI 1.173-1.203) with a CCI threshold of 3.5 having the highest specificity (50.9%) and sensitivity (79.9%) to predict mortality outcome (AUC 0.704, Youden Index 0.31).

Conclusion. In conclusion CCI score is an adequate predictor of hospitalization and in hospital mortality but less so in predicting ICU admission in COVID-19 positive patients.

Disclosures. All Authors: No reported disclosures

29. Sustained Recovery in Patients Admitted to Hospital With COVID-19

Kasper S. Maetstrup, MD; Adrian G. Zucco, MSc; Joanne Reesink, PhD; Cameron MacPherson, Ph.D.; Sisse R. Ostrowski, MD, PhD, DMSc; Carsten Utoft Niemann, PhD MD; Jens Lundgren, MD, DMSc; Marie Helleberg, MD, PhD, DMSc; Righospitalet, Copenhagen University Hospital, Copenhagen, Hovedstaden, Denmark; Centre of Excellence for Health, Immunity and Infections (CHIP) & PERSIMUNE, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Hovedstaden, Denmark; Copenhagen University Hospital, Copenhagen, Hovedstaden, Denmark; Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Hovedstaden, Denmark; Department of Haematology, Righospitalet, Copenhagen University Hospital, Copenhagen, Denmark, Copenhagen, Hovedstaden, Denmark

Session: O-06. COVID-19 Complications, Co-infections and Clinical Outcomes 1

Background. Several interventional Coronavirus Disease 2019 (COVID-19) studies assess outcomes at day 28, but this follow-up time can be too short, since COVID-19 often cause protracted disease. Further, data on mortality and readmissions after discharge are scarce.

Methods. Patients aged 18-100 years and hospitalized with COVID-19 in Eastern Denmark between March 18, 2020 and January 12, 2021, were followed for 91 days after admission. Patients were stratified in a first and second wave, by admissions before or after June 15, 2020, app. when remdesivir and dexamethasone were introduced as standard of care. Sustained recovery was defined as the first date, achieving 14 consecutive days after hospital discharge without an event of readmission or death. Cumulative incidences of sustained recovery were estimated in both waves and in subgroups based on the patient’s maximum level of respiratory support in the first 14 days of admission as a proxy for disease severity. Risk factors for poor outcomes after discharge were assessed in a multivariable cox proportional hazards model.

Results. Overall 3,386 patients were included in the study; 1,137 and 2,249 patients were admitted in the first and second wave, respectively (Table 1). The cumulative incidence of sustained recovery at day 91 was higher in the second (0.79, 95% CI 0.770-0.81) than in the first wave (0.72, 95% CI 0.70-0.75) (Fig. 1A). In both waves, those with more severe disease recovered at a slower rate (Fig. 2B). There were no differences in cumulative incidences of readmissions or deaths at day 91 after discharge between the two waves, cumulative incidence (0.20, 95% CI 0.190-0.21) and (0.11, 95% CI 0.090-0.12), respectively (Fig 1C, Fig 1D). Male sex, high age, cardiovascular disease, diabetes, chronic pulmonary disease, renal disease, malignancies and neurological disease were associated with lower rates of sustained recovery (Table 2).